JUNS

Announcements

Nothing here yet

Daily updates

• Jupiter Neurosciences initiated dosing in its 30-subject Phase 2a RESET trial evaluating JOTROL in Parkinson's disease.Oct 7, 2026
• Jupiter Neurosciences initiated dosing in its 30-patient Phase 2a RESET trial of JOTROL in Parkinson's disease, advancing the program into clinical testing.Oct 6, 2026

FDA designations

Nothing here yet

News

• Jupiter Neurosciences doses the first patient in the Phase 2a RESET trial of JOTROL for Parkinson's diseaseOct 6, 2026
• PharmAla Biotech provided a corporate update, including a U.S. patent grant, an APA-01 regulatory decision, and the appointment of Canaccord Genuity as exclusive investment banking partnerAug 21, 2026
• Jupiter Neurosciences secures exclusive U.S. rights to ALA-002 in a deal worth up to $100 millionJul 21, 2026
• Jupiter Neurosciences secures $100 million term sheet for exclusive U.S. rights to ALA-002 from PharmAla BiotechMay 20, 2026
• PharmAla Biotech signs term sheet to license exclusive U.S. rights for ALA-002 to Jupiter Neurosciences in a deal valued above $100 millionMay 20, 2026